Answers are grounded in this paper and cite their sources.
Outcomes in B-cell acute lymphoblastic leukemia (B-cell ALL) have significantly improved with the use of targeted agents like inotuzumab ozogamicin (InO), blinatumomab and chimeric antigen T-cell therapies [ 1 , 2 ]. InO is an anti-CD22 antibody-drug conjugate approved for treatment of adult patients and recently for pediatric patients with relapsed/refractory (R/R) B-cell ALL [ 3 , 4 ]. A noticeable adverse event (AE) with InO at the dose schedule used in the INO-VATE trial was hepatic toxicity, especially of sinusoidal obstruction syndrome (SOS); long term follow-up from this study showed a rate of SOS of 14% in the InO arm, compared with 2% in the standard of care (SOC) arm [ 5 ]. In this study, more than double the patients in the InO arm compared to the SOC arm had proceeded to an allogeneic hematopoietic stem cell transplantation (HSCT), a known risk factor for SOS [ 6 , 7 ]. In retrospective analysis, the frequency of SOS post-HSCT in InO exposed patients have been around 20% [ 8 , 9 , 10 ]. Other risk factors associated with development of SOS in adult patients exposed to InO and undergoing HSCT include older age, prior liver disease, cumulative InO dosage, prior HSCT, active disease at the time of HSCT, use of dual-alkylator based conditioning, amongst others [ 6 , 9 ].
No takes yet. Share an insight, caveat, or question.
Senapati et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: